TY  - JOUR
AU  - Carli, Francesco
AU  - Di Chiaro, Pierluigi
AU  - Morelli, Mariangela
AU  - Arora, Chakit
AU  - Bisceglia, Luisa
AU  - De Oliveira Rosa, Natalia
AU  - Cortesi, Alice
AU  - Franceschi, Sara
AU  - Lessi, Francesca
AU  - Di Stefano, Anna Luisa
AU  - Santonocito, Orazio Santo
AU  - Pasqualetti, Francesco
AU  - Aretini, Paolo
AU  - Miglionico, Pasquale
AU  - Diaferia, Giuseppe R.
AU  - Giannotti, Fosca
AU  - Liò, Pietro
AU  - Duran-Frigola, Miquel
AU  - Mazzanti, Chiara Maria
AU  - Natoli, Gioacchino
AU  - Raimondi, Francesco
PY  - 2025
DA  - 2025/02/15
TI  - Learning and actioning general principles of cancer cell drug sensitivity
JO  - Nature Communications
SP  - 1654
VL  - 16
IS  - 1
AB  - High-throughput screening of drug sensitivity of cancer cell lines (CCLs) holds the potential to unlock anti-tumor therapies. In this study, we leverage such datasets to predict drug response using cell line transcriptomics, focusing on models’ interpretability and deployment on patients’ data. We use large language models (LLMs) to match drug to mechanisms of action (MOA)-related pathways. Genes crucial for prediction are enriched in drug-MOAs, suggesting that our models learn the molecular determinants of response. Furthermore, by using only LLM-curated, MOA-genes, we enhance the predictive accuracy of our models. To enhance translatability, we align RNAseq data from CCLs, used for training, to those from patient samples, used for inference. We validated our approach on TCGA samples, where patients’ best scoring drugs match those prescribed for their cancer type. We further predict and experimentally validate effective drugs for the patients of two highly lethal solid tumors, i.e., pancreatic cancer and glioblastoma.
SN  - 2041-1723
UR  - https://doi.org/10.1038/s41467-025-56827-5
DO  - 10.1038/s41467-025-56827-5
ID  - Carli2025
ER  - 
